Brendan McDermid/ Reuters Bristol-Myers Squibb announced Monday it would divest one of Celgene‘s most profitable drugs in order to avert regulatory pressure relating to the companies’ proposed merger. The New York-based pharmaceutical company announced its agreement to purchase Celgene for $74 billion back in January. Bristol-Myers will divest Otezla, a drug used to treat psoriasis, […]